Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

All GLG News Analyses Filed Under: Cardiology

Articles with lock require a GLG News subscription
Posted July 6, 2007
For all You Do, This Chip's for You!
Analysis of: Yahoo v/s Google | news.yahoo.com
Author: GLG Member Program Contributor
As reported in the June 26, 2007 online edition of "Yahoo News", Radiofrequency identification tags (RFIDs) are already used by WalMart and other businesses to speed up their shipping systems by sending out small signals that can be scanned more easily than bar codes.  Also, pharmaceutical manufacturers...
Posted June 29, 2007
A coup for Novartis
Analysis of: FDA Gives Go-Ahead to Once-Daily Valsartan-Amlodipine Combination Pill for Hypertension | www.medscape.com
Author: GLG Member Program Contributor
The company now has an ACE-amlodipine and an ARB-amlodipine combination. Though not for first line therapy, many patients require more than a single drug to get to goal. Having options with two excellent drug combos give the physician and patient a heads up for treatment and achieving what is needed...
Posted June 26, 2007
good for IM's limited use for cardiologists
Analysis of: Exforge Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure | pharmalive.com
Author: GLG Member Program Contributor
Like all combo drugs, many IM's will love it, as it is convenient.  Cardiologists hate combo drugs except htn meds in combination with HCTZ.  (eg lotrel, which no cardiologist has ever given).  This is another desparate attempt on Pfizer's behalf to keep branded norvasc alive. &...
Posted June 25, 2007
exforge true observance improvement associating two efficient blockbusters in the treatment of high blood pressure
Analysis of: Exforge Receives Final US Approval as New and Powerful Treatment Option for Patients With High Blood Pressure | pharmalive.com
Author: GLG Member Program Contributor
Two lockbusters have been &associated in one pill to treat hypertension thees are the more efficient drugs today well tolerated with very few side effects 9 out of 10 patients are controlled observance will be improved control as well
Posted June 25, 2007
Nuvelo Pharmaceuticals Phase II trial of a Nematode derived anticoagulant for ACS
Analysis of: Nuvelo Announces Publication Of Phase 2 RNAPc2 Study Results In Journal Of American College Of Cardiology | www.medicalnewstoday.com
Author: GLG Member Program Contributor
With the number of patients admitted annually to US hospitals for ACS currently at one million and trending upward, the research and development of novel anticoagulants such as rNAPc2 has potentially important clinical implications.  Phase II study results of this agent which acts very early in...
Posted June 25, 2007
A boost for the generic
Analysis of: Pfizer Backtracks on the Benefit of Atorvastatin Over Simvastatin: "Programming Error" in Flawed Study Cited | www.medscape.com
Author: GLG Member Program Contributor
This finding should push the use of generic simvastatin in the eyes of PBM and managed care companies. Why use a more expensive drug if a generic form of another will give you similar results.
Posted June 18, 2007
To Echo or not to Echo: that is the Question!
Analysis of: Appropriateness Criteria for Performance of Cardiac Ultrasound Exams Released | www.earthtimes.org
Author: GLG Member Program Contributor
Who has time to study guidelines besides insurance CEO's?? I think insurance companies are the only ones to benefit from these new guidelines. It will only be  a matter of time when echocardiograms will need to be pre-certified. Or better yet, only cardiologists will be allowed to order them!...
Posted June 18, 2007
It's About Time
Analysis of: Appropriateness Criteria for Performance of Cardiac Ultrasound Exams Released | www.earthtimes.org
Author: GLG Member Program Contributor
 - cardiac ultrasound exams are both over and under-used  - there have been no guidelines up till now  - the next step is for insurance companies to implement these    guidelines
David Engler Posted June 12, 2007
Xyzal: Single Isomer Zyrtec, but still SEDATING. Yawn
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: David Engler, Physician The Allergy Clinic
Levoceterizine is the left-handed isomer of ceterizine (Zyrtec).  It gives all the antihistaminic effect of Zyrtec with, maybe, half the sedation.  But it ain't non-sedating!  Look at its own data:  6% sedation with Xyzal, 2% with placebo.  As such, I must respectfully disagree...
Posted June 11, 2007
Ximelagatran effective in stroke prevention
Analysis of: Ximelagatran Comparable to Warfarin in Stroke Prevention | www.medscape.com
Author: Forrest Rubenstein, Cardiac, Thoracic and Vascular Surgeon Rubenstein Cardiovascular and Thoracic Surgery
   Ximalagatran is comparable to coumadin in stroke prevention.  In this analysis of 7000 patients with atrial fibrillation, the stroke rate was less with ximelagatran than with coumadin with a similar bleeding profile.  The combination of aspirin and coumadin did not improve the...
Previous Page : 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 Next241 to 250 of 419

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617